Craft

Standard BioTools

Stock Price

$1.8

2024-10-29

Market Capitalization

$649.5 M

2024-10-29

Revenue

$106.3 M

FY, 2023

Standard BioTools Summary

Company Summary

Overview
Standard BioTools (formerly known as Fluidigm) is a biotechnology company that develops microfluidic-based chips and instrumentation for biological research. Its products include preparatory analytical instruments, imaging systems, microfluidics, accessories, assays and reagents, cytometry kits, etc. The company also provides consulting, compliance, proactive maintenance, panel design, application support, and other services.
Type
Public
Status
Active
Founded
1999
HQ
South San Francisco, CA, US | view all locations
Website
https://www.standardbio.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Michael Egholm

    Michael Egholm, President, Chief Executive Officer and Director

  • Alex Kim

    Alex Kim, Chief Operating Officer

  • Agnieszka Gallagher

    Agnieszka Gallagher, Senior Vice President and Chief Legal Officer

  • Anders Davas

    Anders Davas, Senior Vice President, Global Operations

LocationsView all

15 locations detected

  • South San Francisco, CA HQ

    United States

    2 Tower Place, Suite 2000

  • Sydney, NSW

    Australia

    50 Bridge Street

  • Markham, ON

    Canada

    1380 Rodick Road, Suite 400

  • Shanghai, Shang Hai Shi

    China

    Room 1709, A Building Hongwell International Plaza, No. 1600 West Zhongshan Road

  • Paris, IDF

    France

    1, Avenue de l'atlantique

  • Paris, IDF

    France

    43-47 avenue de la Grande-Armée

and 9 others

Standard BioTools Financials

Summary Financials

Net income (Q3, 2024)
($32.2M)
Cash (Q3, 2024)
$210.6M
Enterprise value
$549.0M

Footer menu